# A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)

> **NCT07164833** · PHASE2 · RECRUITING · sponsor: **Bilix Co.,Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Ischemia Reperfusion Injury
- Cardiac Surgery Associated - Acute Kidney Injury

## Interventions

- **DRUG:** BX-001N Experimental group 1
- **DRUG:** BX-001N Experimental group 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07164833
- **Lead sponsor:** Bilix Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-26
- **Primary completion:** 2026-06
- **Final completion:** 2027-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07164833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07164833, "A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07164833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*